The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before first-line chemotherapy initiation and at the first imaging assessment after chemotherapy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Another chemotherapy regimen, targeted therapy, or immunotherapy
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
RECRUITINGProgression-free survival
The date of first-line chemotherpay initiation to tumor progression or death due to any cause in the absence of progression.
Time frame: Baseline until death from any cause (up to approximately 24 months)
Overall survival
The date of first-line chemotherpay initiation to death due to any cause.
Time frame: Baseline until death from any cause (up to approximately 24 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.